346 related articles for article (PubMed ID: 16870071)
41. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma.
van Adelsberg J; Moy J; Wei LX; Tozzi CA; Knorr B; Reiss TF
Curr Med Res Opin; 2005 Jun; 21(6):971-9. PubMed ID: 15969897
[TBL] [Abstract][Full Text] [Related]
42. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy.
Allen-Ramey FC; Bukstein D; Luskin A; Sajjan SG; Markson LE
J Manag Care Pharm; 2006 May; 12(4):310-21. PubMed ID: 16792437
[TBL] [Abstract][Full Text] [Related]
43. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%.
Becker A; Swern A; Tozzi CA; Yu Q; Reiss T; Knorr B
Curr Med Res Opin; 2004 Oct; 20(10):1651-9. PubMed ID: 15462699
[TBL] [Abstract][Full Text] [Related]
44. Predicting short term response to anti-inflammatory therapy in young children with asthma.
Zielen S; Christmann M; Kloska M; Dogan-Yildiz G; Lieb A; Rosewich M; Schubert R; Rose MA; Schulze J
Curr Med Res Opin; 2010 Feb; 26(2):483-92. PubMed ID: 20001651
[TBL] [Abstract][Full Text] [Related]
45. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
46. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma.
Schuh S; Dick PT; Stephens D; Hartley M; Khaikin S; Rodrigues L; Coates AL
Pediatrics; 2006 Aug; 118(2):644-50. PubMed ID: 16882819
[TBL] [Abstract][Full Text] [Related]
47. Real-life effectiveness of Singulair (montelukast) in 506 children with mild to moderate asthma.
Amirav I
Isr Med Assoc J; 2008 Apr; 10(4):287-91. PubMed ID: 18548983
[TBL] [Abstract][Full Text] [Related]
48. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years.
Nelson KA; Smith SR; Trinkaus K; Jaffe DM
Pediatr Emerg Care; 2008 Jan; 24(1):21-7. PubMed ID: 18165796
[TBL] [Abstract][Full Text] [Related]
49. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis.
Thomas M; Kocevar VS; Zhang Q; Yin DD; Price D
Pediatrics; 2005 Jan; 115(1):129-34. PubMed ID: 15629992
[TBL] [Abstract][Full Text] [Related]
50. Montelukast and airway remodeling in children with chronic persistent asthma: an open study.
Pifferi M; Caramella D; Ragazzo V; De Marco E; Pietrobelli A; Boner AL
Pediatr Allergy Immunol; 2004 Oct; 15(5):472-3. PubMed ID: 15482525
[TBL] [Abstract][Full Text] [Related]
51. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population.
Pathak DS; Davis EA; Stanford RH
Pharmacotherapy; 2002 Feb; 22(2):166-74. PubMed ID: 11837555
[TBL] [Abstract][Full Text] [Related]
52. Inhaled anti-inflammatory pharmacotherapy and subsequent hospitalizations and emergency department visits among patients with asthma in the Texas Medicaid program.
Smith MJ; Rascati KL; McWilliams BC
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):40-6. PubMed ID: 14756463
[TBL] [Abstract][Full Text] [Related]
53. [Utilization and clinical validation of the Spanish version of the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) and the Diary for Caregivers of Asthmatic Children (DCA). VALAIR study].
Alonso Lebrero E
Allergol Immunopathol (Madr); 2000; 28(3):175-83. PubMed ID: 10867390
[TBL] [Abstract][Full Text] [Related]
54. Benefits of a school-based asthma treatment program in the absence of secondhand smoke exposure: results of a randomized clinical trial.
Halterman JS; Szilagyi PG; Yoos HL; Conn KM; Kaczorowski JM; Holzhauer RJ; Lauver SC; Neely TL; Callahan PM; McConnochie KM
Arch Pediatr Adolesc Med; 2004 May; 158(5):460-7. PubMed ID: 15123479
[TBL] [Abstract][Full Text] [Related]
55. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
56. Impact of school-based health centers on children with asthma.
Guo JJ; Jang R; Keller KN; McCracken AL; Pan W; Cluxton RJ
J Adolesc Health; 2005 Oct; 37(4):266-74. PubMed ID: 16182136
[TBL] [Abstract][Full Text] [Related]
57. Comparative resource utilization in medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy.
Stanford RH; Riedel AA; Johnson JC; Astry CL
Clin Ther; 2010 Sep; 32(10):1782-93. PubMed ID: 21194602
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of montelukast as monotherapy in children with mild persistent asthma.
Ghosh G; Manglik AK; Roy S
Indian Pediatr; 2006 Sep; 43(9):780-5. PubMed ID: 17033116
[TBL] [Abstract][Full Text] [Related]
59. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
60. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast.
Rabinovitch N; Strand M; Stuhlman K; Gelfand EW
J Allergy Clin Immunol; 2008 Jun; 121(6):1365-71. PubMed ID: 18439662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
